Tags

Type your tag names separated by a space and hit enter

Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease.
Int Heart J 2005; 46(2):255-64IH

Abstract

Atherosclerosis is a disease of the arterial wall, with increasing wall thickness representing an early event in the progression of the disease. It has been suggested that iron overload, as assessed by increased serum ferritin concentration, may be a risk factor for atherosclerosis. The aim of this study was to investigate the relationship between the influence of intravenous (IV) iron therapy and ferritin levels and carotid intima media thickness (C-IMT) in dialysis patients. Sixty patients (51 +/- 14) years were divided into two groups according to their IMT obtained by ultrasound; group I (high risk) and group II (low risk). The parameters assessed were serum creatinine, urea, calcium, phosphorus, hemoglobin, albumin, uric acid, iron, ferritin, and lipid levels. Thirty-eight patients (88%) in group I and 5 patients (12%) in group II received IV iron therapy while 5 patients (29%) in group I and 12 patients (71%) in group II (P < 0.001) did not receive IV iron therapy. Ferritin levels were higher in group I than in group II (581 +/- 303 and 306 +/- 224) (P < 0.001). C-IMT measurements correlated with serum ferritin and with the intravenous iron dose received during the 24 months preceding the study (r = 0.315, P = 0.015; r = 0.471, P = 0.001). The findings indicate that IV iron therapy and elevated serum ferritin levels may cause an increase in the incidence of atherosclerosis.

Authors+Show Affiliations

Depertment of Nephrology, Gazi University, Faculty of Medicine, Besevler-Ankara, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15876809

Citation

Reis, Kadriye Altok, et al. "Intravenous Iron Therapy as a Possible Risk Factor for Atherosclerosis in End-stage Renal Disease." International Heart Journal, vol. 46, no. 2, 2005, pp. 255-64.
Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J. 2005;46(2):255-64.
Reis, K. A., Guz, G., Ozdemir, H., Erten, Y., Atalay, V., Bicik, Z., ... Sindel, S. (2005). Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. International Heart Journal, 46(2), pp. 255-64.
Reis KA, et al. Intravenous Iron Therapy as a Possible Risk Factor for Atherosclerosis in End-stage Renal Disease. Int Heart J. 2005;46(2):255-64. PubMed PMID: 15876809.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. AU - Reis,Kadriye Altok, AU - Guz,Galip, AU - Ozdemir,Hakan, AU - Erten,Yasemin, AU - Atalay,Veli, AU - Bicik,Zerrin, AU - Ozkurt,Zubeyde Nur, AU - Bali,Musa, AU - Sindel,Sukru, PY - 2005/5/7/pubmed PY - 2005/8/6/medline PY - 2005/5/7/entrez SP - 255 EP - 64 JF - International heart journal JO - Int Heart J VL - 46 IS - 2 N2 - Atherosclerosis is a disease of the arterial wall, with increasing wall thickness representing an early event in the progression of the disease. It has been suggested that iron overload, as assessed by increased serum ferritin concentration, may be a risk factor for atherosclerosis. The aim of this study was to investigate the relationship between the influence of intravenous (IV) iron therapy and ferritin levels and carotid intima media thickness (C-IMT) in dialysis patients. Sixty patients (51 +/- 14) years were divided into two groups according to their IMT obtained by ultrasound; group I (high risk) and group II (low risk). The parameters assessed were serum creatinine, urea, calcium, phosphorus, hemoglobin, albumin, uric acid, iron, ferritin, and lipid levels. Thirty-eight patients (88%) in group I and 5 patients (12%) in group II received IV iron therapy while 5 patients (29%) in group I and 12 patients (71%) in group II (P < 0.001) did not receive IV iron therapy. Ferritin levels were higher in group I than in group II (581 +/- 303 and 306 +/- 224) (P < 0.001). C-IMT measurements correlated with serum ferritin and with the intravenous iron dose received during the 24 months preceding the study (r = 0.315, P = 0.015; r = 0.471, P = 0.001). The findings indicate that IV iron therapy and elevated serum ferritin levels may cause an increase in the incidence of atherosclerosis. SN - 1349-2365 UR - https://www.unboundmedicine.com/medline/citation/15876809/Intravenous_iron_therapy_as_a_possible_risk_factor_for_atherosclerosis_in_end_stage_renal_disease_ L2 - http://japanlinkcenter.org/JST.JSTAGE/ihj/46.255?from=PubMed DB - PRIME DP - Unbound Medicine ER -